VEGFA and neoplasm: Acquired resistance is common in VEGF-targeted therapies, and the mechanisms that underlie the modest efficacy of anti-angiogenesis therapies may involve the active recruitment of macrophages to the tumor microenvironment, where they are responsible for the emergence of anti-VEGF therapy resistance [98].